Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares RepurchasedShort-Term Debt repayments
Ratios

Ani Pharmaceuticals (ANIP) Receivables - Net (2016 - 2025)

Ani Pharmaceuticals' Receivables - Net history spans 14 years, with the latest figure at $281.1 million for Q4 2025.

  • For Q4 2025, Receivables - Net rose 26.77% year-over-year to $281.1 million; the TTM value through Dec 2025 reached $281.1 million, up 26.77%, while the annual FY2025 figure was $281.1 million, 26.77% up from the prior year.
  • Receivables - Net for Q4 2025 was $281.1 million at Ani Pharmaceuticals, up from $252.6 million in the prior quarter.
  • Across five years, Receivables - Net topped out at $281.1 million in Q4 2025 and bottomed at $91.9 million in Q1 2021.
  • The 5-year median for Receivables - Net is $169.3 million (2024), against an average of $171.6 million.
  • The largest annual shift saw Receivables - Net skyrocketed 62.35% in 2022 before it dropped 3.95% in 2024.
  • A 5-year view of Receivables - Net shows it stood at $128.5 million in 2021, then rose by 28.72% to $165.4 million in 2022, then decreased by 2.03% to $162.1 million in 2023, then soared by 36.8% to $221.7 million in 2024, then increased by 26.77% to $281.1 million in 2025.
  • Per Business Quant, the three most recent readings for ANIP's Receivables - Net are $281.1 million (Q4 2025), $252.6 million (Q3 2025), and $225.7 million (Q2 2025).